2025
Etomidate vs Ketamine-Propofol for Induction of Anesthesia in Coronary Artery Bypass Grafting: An Updated Systematic Review and Meta-Analysis.
Kumar N, Bardia A, Fitzsimons M, Essandoh M, Mitchell J, Falkson S, Dalia A, Tang J, Sawyer T, Iyer M. Etomidate vs Ketamine-Propofol for Induction of Anesthesia in Coronary Artery Bypass Grafting: An Updated Systematic Review and Meta-Analysis. Seminars In Cardiothoracic And Vascular Anesthesia 2025, 10892532251332079. PMID: 40221834, DOI: 10.1177/10892532251332079.Peer-Reviewed Original ResearchCoronary Artery Bypass GraftingSystemic vascular resistanceWeighted mean differenceMean arterial pressureArtery Bypass GraftingBypass GraftingExcerpta Medica DatabaseUnited States National Library of Medicine databaseCardiac surgical populationInduction of general anesthesiaBoluses of vasopressorsNational Library of Medicine databaseResponse to hypotensionCardiovascular depressant effectsCABG surgery patientsSerum cortisol levelsInduction of anesthesiaSuperior hemodynamic profileRandomized Controlled TrialsCardiac indexHemodynamic profileSurgery patientsSurgical populationVascular resistanceCo-administered
2020
Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy
Cui X, Ma C, Vasudevaraja V, Serrano J, Tong J, Peng Y, Delorenzo M, Shen G, Frenster J, Morales R, Qian W, Tsirigos A, S A, Jain R, Kurz S, Sulman E, Placantonakis D, Snuderl M, Chen W. Dissecting the immunosuppressive tumor microenvironments in Glioblastoma-on-a-Chip for optimized PD-1 immunotherapy. ELife 2020, 9: e52253. PMID: 32909947, PMCID: PMC7556869, DOI: 10.7554/elife.52253.Peer-Reviewed Original ResearchConceptsProgrammed cell death protein 1Immunosuppressive tumor microenvironmentTumor-associated macrophagesTumor microenvironmentCD163+ tumor-associated macrophagesPD-1/PD-L1 immune checkpointCSF-1R inhibitor BLZ945Molecularly distinct GBM subtypesCell death protein 1Anti-PD-1 immunotherapyT cell functionNivolumab efficacyImmunotherapy efficacyImmune checkpointsImmune signaturesImmunosuppressive mechanismsT cellsM2-TAMsCo-administeredGlioblastoma patientsIL-10CSF-1RCSF-1ImmunotherapyProneural glioblastoma
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply